Ignite Creation Date:
2024-05-06 @ 4:12 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04900454
Status:
COMPLETED
Last Update Posted:
2024-04-08
First Post:
2021-05-20
Brief Title:
Allogeneic Natural Killer NK Cell Therapy in Subjects Hospitalized for COVID-19
Sponsor:
Coeptis Therapeutics
Organization:
Coeptis Therapeutics
Study Overview
Official Title:
A Phase 1 Study of DVX201 an Allogeneic Natural Killer NK Cell Therapy in Subjects Hospitalized for COVID-19
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to determine the highest tolerated dose of an investigational cell therapy called DVX201 in patients hospitalized with COVID-19 DVX201 is an allogeneic NK natural killer cell therapy NK cells are a normal part of your immune system that have the ability to identify and kill cells in the body that are infected by viruses such as COVID-19 There is evidence that both NK cell exhaustion and low numbers of NK cell in the blood occur in COVID-19 patients and this may contribute to worsening of the infection Therefore infusion of healthy functional NK cells like DVX201 may help overcome COVID-19 infection and prevent progression of the disease This study is being done to look at the safety and tolerability of DVX201 in patients with COVID-19 and to gather information on how COVID-19 responds to treatment with DVX201
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RG1121470 | OTHER | Fred Hutchinson Cancer Research Center | None |